[1] RODIG S J, MERAZ M A, WHITE J M, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell, 1998, 93(3):373-383.
[2] KREMPLER A, QI Y, TRIPLETT A A, et al. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis, 2004, 40(1):52-57.
[3] O′SHEA J J, PESU M, BORIE D C, et al. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov, 2004, 3(7):555-564.
[4] SANDA T, TYNER J W, GUTIERREZ A, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov, 2013, 3(5):564-577.
[5] FURTEK S L, BACKOS D S, MATHESON C J, et al. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem Biol, 2016, 11(2):308-318.
[6] XU S, NEAMATI N. Gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets, 2013, 17(11):1303-1328.
[7] XIONG A, YANG Z, SHEN Y, et al. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers, 2014, 6(2):926-957.
[8] KISSELEVA T, BHATTACHARYA S, BRAUNSTEIN J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene, 2002, 285(1-2):1-24.
[9] YU H, LEE H, HERRMANN A, et al. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer, 2014, 14(11):736-746.
[10] JOHNSON D E, O′KEEFE R A, GRANDIS J R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol, 2018, 15(4):234-248.
[11] CARPENTER R L, LO H W. STAT3 target genes relevant to human cancers. Cancers, 2014, 6(2):897-925.
[12] AKIRA S, NISHIO Y, INOUE M, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell, 1994, 77(1):63.
[13] YOU W, TANG Q, ZHANG C, et al. IL-26 Promotes the proliferation and survival of human gastric cancer cells by regulating the balance of STAT1 and STAT3 activation. PLoS One, 2013, 8(5):e63588.
[14] ZHAO G, ZHANG J G, SHI Y, et al. MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. PLoS One, 2013, 8(9):e73803.
[15] MCDOUGALL S R, ANDERSON A R A, CHAPLAIN M A J. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol, 2006, 241(3):564-589.
[16] KALLURI R, ISRAEL B. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer, 2003, 3(6):422-433.
[17] ZUGOWSKI C, LIEDER F, GASCH J, et al. STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem, 2011, 392(5):449-459.
[18] TSUJITA Y, HORIGUCHI A, TASAKI S, et al. STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells. Oncol Rep, 2017, 38(4):2197-2204.
[19] SNYDER M, HUANG X Y, ZHANG J J. Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J Biol Chem, 2011, 286(45):38886-38893.
[20] LI L, WANG S, YANG X, et al. Traditional Chinese medicine, Fuzheng Kang-Ai decoction, inhibits metastasis of lung cancer cells through the STAT3 / MMP9 pathway. Mol Med Rep, 2017, 16(3):2461-2468.
[21] NIU G, WRIGHT K L, HUANG M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 2002, 21(13):2000-2008.
[22] BU L L, YU G T, WU L, et al. STAT3 Induces immunosuppression by upregulating PD-1/PD-L1 in HNSCC. J Dent Res, 2017, 96(9):1027-1034.
[23] LOU W, CHEN Y, ZHU K, et al. Polyphyllin I overcomes EMT-associated resistance to erlotinib in lung cancer cells via IL-6/STAT3 pathway inhibition. Biol Pharm Bull, 2017, 40(8):1306-1313.
[24] ERNST M, BUCHERT M. The JAK/STAT3 axis: a comprehensive drug target for solid malignancies. Semin Cancer Biol, 2017,45:13-22.
[25] FURQAN M, MUKHI N, LEE B, et al. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res, 2013, 1(1):5.
[26] HEDVAT M, HUSZAR D, HERRMANN A, et al. The JAK2 inhibitor, AZD1480, potently blocks Stat3 signaling and oncogenesis in solid tumors michael. Cancer Cell, 2010, 16(6):487-497.
[27] CHAI E Z P, SHANMUGAM M K, ARFUSO F, et al. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol Ther, 2016, 162: 86-97.
[28] HU Y, DONG X, LIU X, et al. Enhanced antitumor activity of cetuximab in combination with the Jak inhibitor CYT387 against non-small-cell lung cancer with various genotypes. Mol Pharm, 2016, 13(2):689-697.
[29] OCHI N, ISOZAKI H, TAKEYAMA M, et al. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal growth factor receptor mutation-positive non-small cell lung cancer. Exp Cell Res, 2016, 344(2):194-200.
[30] YOUNES A, ROMAGUERA J, FANALE M, et al. Phase I study of a novel oral janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol, 2015, 30(33):4161-4168.
[31] SAU S, MONDAL S K, KASHAW S K, et al. Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug. Mol Cell Biochem, 2017,436(1-2):1-18.
[32] NAM S, WEN W, SCHROEDER A, et al. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol, 2013, 7(3):369-378.
[33] BRAMBILLA L, GENINI D, LAURINI E, et al. Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3). Mol Oncol, 2015, 9(6):1194-1206.
[34] HAYAKAWA F, SUGIMOTO K, HARADA Y, et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J, 2013, 3(11):e166.
[35] WONG A L, SOO R A, TAN D S, et al. Phase Ⅰ and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol, 2015, 26(5):998-1005.
[36] OGURA M, UCHIDA T, TERUI Y, et al. Phase Ⅰ study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci, 2015, 106(7):896-901.
[37] ZHANG X, YUE P, PAGE B D G, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci USA, 2012, 109(24):9623-9628.
[38] HUANG W, DONG Z, CHEN Y, et al. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene, 2016, 35(6):783-792.
[39] LI Y, ROGOFF H A, KEATES S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA, 2015, 112(6):1839-1844.
[40] CAFFERKEY C, CHAU I. Novel STAT 3 inhibitors for treating gastric cancer. Expert Opin Investig Drugs, 2016, 25(9):1023-1031.
[41] CHIARLE R, SIMMONS W J, CAI H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med, 2005, 11(6):623-629.
[42] HONG D, KURZROCK R, KIM Y, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med, 2015, 7(314):314ra185.
[43] TIMOFEEVA O A, TARASOVA N I, ZHANG X, et al. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci USA, 2013, 110(4):1267-1272.